Citius Pharmaceuticals, Inc.

NasdaqCM:CTXR Rapporto sulle azioni

Cap. di mercato: US$25.8m

Citius Pharmaceuticals Crescita futura

Future criteri di controllo 5/6

Si prevede che Citius Pharmaceuticals aumenterà gli utili e i ricavi rispettivamente del 53% e 48.3% all'anno, mentre si prevede che l'EPS crescerà del 53.2% all'anno.

Informazioni chiave

53.0%

Tasso di crescita degli utili

53.2%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili23.7%
Tasso di crescita dei ricavi48.3%
Rendimento futuro del capitale proprion/a
Copertura analitica

Low

Ultimo aggiornamento22 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully

Apr 06
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate

Dec 08
We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate

Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?

Aug 01
Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Apr 12
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

Dec 25
Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK

Sep 28

Citius Pharmaceuticals GAAP EPS of -$0.06

Aug 11

Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

Aug 05
Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK

Jul 12

Citius Pharmaceuticals: Hoping For A Turnaround Strategy

Jul 05

Critical Care Biopharma - Citius Pharmaceuticals

Apr 13

Citius: 2022 Is A Year Of Catalysts

Mar 28

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Dec 04
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization

Sep 26

Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth

Aug 28
Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth

Citius: Halt For Superiority On The Horizon

Jun 15

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

May 15
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Citius Pharmaceuticals shares rise in anticipation of Mino-Lok phase 3 results

Apr 26

Is Citius Pharmaceuticals (NASDAQ:CTXR) In A Good Position To Deliver On Growth Plans?

Dec 18
Is Citius Pharmaceuticals (NASDAQ:CTXR) In A Good Position To Deliver On Growth Plans?

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:CTXR - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
9/30/20273532002092092
9/30/2026178901601603
9/30/202546-338383
9/30/2024N/A-39-28-313
6/30/2024N/A-40-29-29N/A
3/31/2024N/A-37-30-30N/A
12/31/2023N/A-39-30-30N/A
9/30/2023N/A-34-29-29N/A
6/30/2023N/A-31-29-29N/A
3/31/2023N/A-31-27-27N/A
12/31/2022N/A-28-29-29N/A
9/30/2022N/A-34-28-28N/A
6/30/2022N/A-31-68-28N/A
3/31/2022N/A-29-65-25N/A
12/31/2021N/A-26-59-19N/A
9/30/2021N/A-25-64-24N/A
6/30/2021N/A-24-22-22N/A
3/31/2021N/A-21-21-21N/A
12/31/2020N/A-21-21-21N/A
9/30/2020N/A-18-17-17N/A
6/30/2020N/A-17-16-16N/A
3/31/2020N/A-17-16-16N/A
12/31/2019N/A-16-15-15N/A
9/30/2019N/A-16-12-12N/A
6/30/2019N/A-15-12-12N/A
3/31/2019N/A-12-11-11N/A
12/31/2018N/A-13-11-11N/A
9/30/2018N/A-13-11-11N/A
6/30/2018N/A-13-12-12N/A
3/31/2018N/A-13N/A-12N/A
12/31/2017N/A-11N/A-9N/A
9/30/2017N/A-10N/A-8N/A
6/30/2017N/A-10N/A-6N/A
3/31/2017N/A-11N/A-6N/A
12/31/2016N/A-9N/A-7N/A
9/30/2016N/A-8N/A-6N/A
6/30/2016N/A-7N/A-5N/A
3/31/2016N/A-4N/A-3N/A
12/31/2015N/A-3N/A-2N/A
9/30/2015N/A-3N/A-2N/A
6/30/2015N/A-3N/A-2N/A
3/31/2015N/A-2N/A-1N/A
12/31/2014N/A-2N/A-1N/A
9/30/2014N/A-1N/A-1N/A
6/30/2014N/A-1N/A-1N/A
3/31/2014N/A-1N/A-1N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che CTXR diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 2.6% ).

Guadagni vs Mercato: Si prevede che CTXR diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.

Guadagni ad alta crescita: Si prevede CTXR diventerà redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di CTXR ( 48.3% all'anno) crescerà più rapidamente del mercato US ( 8.9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di CTXR ( 48.3% all'anno) crescerà più rapidamente di 20% all'anno.


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di CTXR è previsto essere elevato tra 3 anni


Scoprire le aziende in crescita